Day: January 12, 2021

Dr. Jain brings deep expertise in the design and execution of complex clinical trials, having overseen the development of more than 15 new chemical entities and marketed productsDr. Jain’s broad and diverse clinical experience makes her uniquely well-suited to lead the initiation of multiple Phase 3 programs for IMVT-1401 across different therapeutic areasNEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) — Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the appointment of Rita Jain, M.D. as Chief Medical Officer. Dr. Jain brings over 20 years of drug development and biopharmaceutical leadership experience to Immunovant, including industry-leading experience in both early and late phase development.“We are thrilled to announce...

NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) today announced with great sadness that Director Jack H. Nusbaum passed away unexpectedly on January 11, 2021.Mr. Nusbaum has served as a member of Cowen’s Board since November 2009. He has been an advisor and friend to members of the Company’s leadership for over 30 years. Mr. Nusbaum was also a Senior Partner of the New York law firm of Willkie Farr & Gallagher LLP, serving as the firm’s Chairman from 1987 through 2009 and a partner in that firm for fifty years.Jeffrey M. Solomon, Chair and Chief Executive Officer of Cowen, said, “All of us at Cowen are deeply saddened by the sudden passing of our long-time board member Jack Nusbaum. He was not only a trusted advisor and good friend; he was a member of our family. His wise counsel,...

RALEIGH, N.C., Jan. 12, 2021 (GLOBE NEWSWIRE) — American National Bank and Trust Company has opened its Raleigh office at 3700 Glenwood Avenue following an announcement in late 2019 stating its plans to move into the Raleigh market.American National has a team of local commercial relationship managers who have been actively serving customers throughout the Triangle area. The team has been working from temporary space as it searched for the right office location. The new suite occupies 3,640 square feet on the third floor of the 3700 Glenwood office building at the intersection of I-440 and Glenwood Avenue.Cindy Vogler serves as the NC Triangle Market President for American National Bank & Trust Company. Vogler, a longtime Raleigh and Cary resident and graduate of the University of North Carolina, has more than 35 years of banking...

SAN DIEGO, Jan. 12, 2021 (GLOBE NEWSWIRE) — BIONANO GENOMICS, INC. (Nasdaq: BNGO), announced today the closing of its previously announced underwritten public offering of 33,368,851 shares of its common stock, including 4,352,458 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a price to the public of $3.05 per share. The gross proceeds to Bionano from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $101.8 million.Oppenheimer & Co. Inc. acted as the sole book-running manager for the offering. BTIG, LLC acted as the lead manager, and Ladenburg Thalmann & Co. Inc. and Maxim Group LLC acted as the co-managers.The shares were offered pursuant to a “shelf” registration statement on Form S-3...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATESTORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) — Mount Logan Capital Inc. (NEO: MLC) (“Mount Logan,” or the “Company”) announces that Chief Financial Officer and Corporate Secretary Edward (Ted) Gilpin has communicated his plans to retire and that Jason T. Roos will succeed him as the Company’s Chief Financial Officer and Corporate Secretary effective as of March 1, 2021. Mr. Gilpin will remain Chief Financial Officer and Corporate Secretary through March 1, 2021 to ensure a smooth transition, following which Mr. Roos will formally assume these positions.“It’s been my pleasure to serve as the Company’s Chief Financial Officer during a time that the Company continued to grow and scale its business and accelerate its transition...

TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) — Stroud Resources Ltd. (TSXV-SDR) (“Stroud” or “Company”) is pleased to announce the appointment of Mr. Jeff Kennedy to the Board of Directors (the “Board”) as an independent non-executive director and Chairman of the Audit Committee.Howard Atkinson, Chairman of the Board of the Company, commented, “We are delighted to welcome Jeff Kennedy to the Stroud Board. Jeff’s financial expertise and experience in the capital markets sector will undoubtably benefit the company as we advance the Santo Domingo Project.”The Company also announced the acceptance of Mr. Grant Walsh’s resignation as an independent director. On behalf of the Board, “I would like to thank Mr. Walsh for his many contributions to Stroud over the past 8 years and wish him success on his...

VICTOR, N.Y., Jan. 12, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it has closed its sale of the Paul Masson Grande Amber Brandy brand, related inventory, and interests in certain contracts to Sazerac for approximately $265 million, subject to certain post-closing adjustments.“The closure of this sale concludes a series of transactions within our wine and spirits business designed to help accelerate revenue growth and operating margin performance by advancing our vision of building a winning portfolio of distinctive, higher-end brands,” said Bill Newlands, Constellation Brands’ president and chief executive officer. “With these transactions now behind us, our team can more fully concentrate our resources and focus behind a smaller set of more...

INDIANA, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) — First Commonwealth Financial Corporation (NYSE: FCF) announced today that it will host a conference call on Wednesday, January 27, 2021 at 2:00 p.m. Eastern Time to discuss financial results for the quarter and year ended December 31, 2020. The call will be hosted by T. Michael Price, President and Chief Executive Officer. He will be joined by James R. Reske, Executive Vice President and Chief Financial Officer, Jane Grebenc, Executive Vice President and Chief Revenue Officer and Brian G. Karrip, Executive Vice President and Chief Credit Officer. First Commonwealth will issue a press release reporting its Fourth Quarter and Full Year 2020 financial results after the market closes on Tuesday, January 26, 2021.Conference Call InformationTo listen to the conference call, either dial the...

EDISON, N.J., Jan. 12, 2021 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos”), a leading provider of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today announced Joe Mastrangelo, Chief Executive Officer, and Sagar Kurada, Chief Financial Officer, will present at the following investor conferences:The Bank of America Merrill Lynch Battery and Storage Virtual Conference on Tuesday, January 19, 2021. The presentation will commence at approximately 9:45 a.m. Eastern Time.The Northland SPAC Virtual Investor Conference on Wednesday, January 20, 2021. The presentation will commence at approximately 10:00 a.m. Eastern Time.A live webcast and replay of the presentations will be available through Eos’s Investor Relations website at https://investors.eose.com.About EosEos...

COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) — Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent Office (the “EPO”) again has rescheduled the oral hearing of the appeal against the decision of the Opposition Division that revoked the EP2801355 patent (the “’355 Patent”). The new hearing date is set for September 6, 2021.About Forward Pharma:Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement...